Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
07:12:54 EDT Sun 05 May 2024
Enter Symbol
or Name
USA
CA



News for U:NVCR from 2023-05-04 to 2024-05-03 - 33 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-02 07:01U:NVCRNews ReleaseNovocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
2024-05-02 07:00U:NVCRNews ReleaseNovocure Reports First Quarter 2024 Financial Results
2024-04-24 10:45U:NVCRNews ReleaseResults of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
2024-04-05 07:00U:NVCRNews ReleaseNovocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
2024-04-01 07:00U:NVCRNews ReleaseNovocure to Report First Quarter 2024 Financial Results
2024-03-27 07:00U:NVCRNews ReleaseMETIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
2024-03-11 07:00U:NVCRNews ReleaseINNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
2024-01-18 07:00U:NVCRNews ReleaseNovocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
2024-01-09 07:00U:NVCRNews ReleaseNovocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
2024-01-08 07:00U:NVCRNews ReleaseNovocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
2024-01-04 16:05U:NVCRNews ReleaseNovocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
2023-12-27 07:00U:NVCRNews ReleaseNovocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference
2023-11-28 07:30U:NVCRNews ReleaseNovocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability
2023-11-21 07:00U:NVCRNews ReleaseNovocure to Participate in 35th Annual Piper Sandler Healthcare Conference
2023-11-10 08:00U:NVCRNews ReleaseNovocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting
2023-10-26 07:00U:NVCRNews ReleaseNovocure Reports Third Quarter 2023 Financial Results
2023-10-15 18:05U:NVCRNews ReleaseNovocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023
2023-10-12 08:00U:NVCRNews ReleaseNovocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program
2023-10-02 07:00U:NVCRNews ReleaseNovocure to Report Third Quarter 2023 Financial Results
2023-09-29 17:00U:NVCRNews ReleaseNovocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting
2023-09-08 16:01U:NVCRNews ReleaseNovocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer
2023-08-29 18:31U:NVCRNews ReleaseNovocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
2023-08-28 07:00U:NVCRNews ReleaseNovocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer
2023-08-25 07:00U:NVCRNews ReleaseNovocure to Participate in Upcoming Investor Conferences
2023-08-13 04:01U:NVCRNews ReleaseNVCR FINAL DEADLINE FRIDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages NovoCure Limited Investors to Secure Counsel Before Important August 18 Deadline in Securities Class Action - NVCR
2023-07-27 07:00U:NVCRNews ReleaseNovocure Reports Second Quarter 2023 Financial Results
2023-07-21 08:00U:NVCRNews ReleaseNovocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer
2023-07-03 08:00U:NVCRNews ReleaseNovocure to Report Second Quarter 2023 Financial Results
2023-06-12 20:27U:NVCRNews ReleaseNVCR NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of NovoCure Limited
2023-06-06 08:06U:NVCRNews ReleaseZai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
2023-06-06 08:00U:NVCRNews ReleaseLUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
2023-06-01 07:01U:NVCRNews ReleaseNovocure Pledges $3 Million to Conquer Cancer ‚ ®, the ASCO Foundation, to Support Cancer Research and Education
2023-05-04 07:00U:NVCRNews ReleaseNovocure Reports First Quarter 2023 Financial Results